Dosing & Uses
Bladder Cancer
Pending FDA approval as intravesical administration for high-risk BCG-unresponsive non-muscle invasive bladder cancer
Next:
Pharmacology
Mechanism of Action
Oportuzumab monatox is a recombinant fusion protein comprising a humanized anti-EpCAM single-chain antibody linked to Pseudomonas exotoxin A
Once bound to the cancer cell, the drug is internalized and the toxin moiety released into the cytosol where it induces apoptosis
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
